Strategic Acquisition IMARC Research was acquired by Avania LLC in June 2021, positioning it within a larger global medical technology CRO ecosystem, which could enhance cross-selling opportunities and broader service integration.

Market Focus With a specialized focus on FDA and international approvals for clinical trials, IMARC presents potential value for companies seeking regulatory guidance and compliant trial management in the medical device sector.

Service Expertise IMARC's services include cost-effective monitoring, auditing, and training, making it attractive to clinical research organizations and sponsors aiming to improve trial quality and compliance efficiency.

Growth Potential Operating within the research services industry with revenues between 1 and 10 million dollars and a dedicated team of up to 200 employees, IMARC shows growth opportunities aligned with expanding clinical trials worldwide.

Digital Presence IMARC leverages a range of tech tools and social media channels including HubSpot, LinkedIn, and Twitter, indicating modern digital marketing approaches that can be expanded to reach potential clients and partners.